CLINICAL_TRIALS
trial_result
· 2024-12-11
Clinical Trial Update: A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients [Phase 3]
Summary
This document provides a Phase 3 open-label safety and efficacy update for TNX-102 SL tablets in fibromyalgia patients, with results posted on 2024-12-11.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Tonix Pharmaceuticals, Inc. | Conditions: Primary Fibromyalgia | Phase 3 | Status: COMPLETED | Results posted: 2024-12-11